Xencor (XNCR) Asset Writedowns and Impairment (2013 - 2026)
Xencor (XNCR) posted quarterly Asset Writedowns and Impairment of -$8.3 million for Q4 2025, down 629.58% quarter-over-quarter from $1.6 million in Q3 2025.
Powered by 
Analysis
Xencor (XNCR) Asset Writedowns and Impairment (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Asset Writedowns and Impairment for 13 consecutive years, with -$8.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to -$8.3 million; the TTM figure through Mar 2026 stood at -$4.9 million (down 204.74% YoY), while the FY2024 annual figure was $20.4 million, changed N/A from the prior year.
- Asset Writedowns and Impairment declined to -$8.3 million in Q4 2025 per XNCR's latest filing, from $1.6 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $20.6 million in Q1 2024 and bottomed at -$8.3 million in Q4 2025.
- Historically, Asset Writedowns and Impairment has averaged $1.4 million across 5 years, with a median of $253500.0 in 2021.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment sank 694.69% — and 2025, when it soared 944.55%.
- Xencor's Asset Writedowns and Impairment stood at $207000.0 in 2021, then tumbled by 694.69% to -$1.2 million in 2022, then jumped by 35.26% to -$797000.0 in 2023, then jumped by 72.4% to -$220000.0 in 2024, then tumbled by 3667.27% to -$8.3 million in 2025.
- Business Quant data shows XNCR's Asset Writedowns and Impairment at -$8.3 million in Q4 2025, $1.6 million in Q3 2025, and $1.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 797,000.00 |
| Dec 31, 2025 | 881,000.00 |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.86 Mn |
| Mar 31, 2025 | 4.87 Mn |
| Jun 30, 2024 | -220,000.00 |
| Mar 31, 2024 | 20.65 Mn |
| Dec 31, 2023 | 470,000.00 |
| Mar 31, 2023 | 321,000.00 |
| Dec 31, 2022 | 179,000.00 |
| Sep 30, 2022 | 300,000.00 |
| Jun 30, 2022 | 700,000.00 |
| Mar 31, 2022 | 311,000.00 |
| Dec 31, 2021 | 207,000.00 |
| Sep 30, 2021 | 600,000.00 |
| Jun 30, 2021 | 117,000.00 |
| Mar 31, 2021 | 193,000.00 |
| Dec 31, 2020 | 132,000.00 |
| Sep 30, 2020 | 236,000.00 |
| Jun 30, 2020 | 139,000.00 |